Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) — Capital Reinvestment Ratio

Latest as of September 2025: 0.59x

Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) has a Capital Reinvestment Ratio of 0.59x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥15.57 Million) in capital expenditures (CN¥9.26 Million). See Wuhan Easy Diagnosis Biomedicine Co Ltd (002932) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.59x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥15.57 Million
CNY

Capital Expenditures

CN¥9.26 Million
CNY

Data as of

Sep 2025
Most recent filing

Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Capital Reinvestment Ratio (2012–2023)

This chart tracks Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's Capital Reinvestment Ratio across 12 annual periods.

Annual Capital Reinvestment Ratio for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2012–2023)

Year-by-year Capital Reinvestment Ratio for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2012 to 2023. For live market cap and broader valuation context, see Wuhan Easy Diagnosis Biomedicine Co Ltd (002932) total market value.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2023 0.28x CN¥392.50 Million CN¥109.97 Million ▲ +258.8%
2022 0.08x CN¥4.01 Billion CN¥313.38 Million ▼ -15.0%
2021 0.09x CN¥1.13 Billion CN¥103.57 Million ▲ +16.9%
2020 0.08x CN¥359.68 Million CN¥28.28 Million ▼ -94.5%
2019 1.42x CN¥22.49 Million CN¥31.94 Million ▲ +60.6%
2018 0.88x CN¥53.67 Million CN¥47.48 Million ▼ -9.6%
2017 0.98x CN¥46.50 Million CN¥45.52 Million ▲ +43.1%
2016 0.68x CN¥58.86 Million CN¥40.27 Million ▲ +2509.5%
2015 0.03x CN¥45.02 Million CN¥1.18 Million ▼ -89.8%
2014 0.26x CN¥16.47 Million CN¥4.24 Million ▼ -40.7%
2013 0.43x CN¥6.30 Million CN¥2.73 Million ▼ -23.1%
2012 0.56x CN¥1.03 Million CN¥582.99K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow